Is vaccination against human papillomavirus a possibility?

Lancet

Volumn 351, Issue SUPPL.3, 1998, Pages 22-24

  Galloway, Denise A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS VACCINE;

GENITAL TRACT CANCER; GENITAL TRACT INFECTION; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; SHORT SURVEY; VIRUS CAPSID; VIRUS GENOME; WART VIRUS;

EID: 0032551163     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)90007-1     Document Type: Article

References (29)

1. Ho G, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-28.
2. Bauer HM, Ting Y, Greer CE, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265: 472-77.
3. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 1272-78.
4. VanDriel WJ, Ressing ME, Brandt RM, et al. The current status of therapeutic HPV vaccine. Ann Med 1996; 28: 471-77.
5. Christensen ND, Kreider JW, Shah KV, Rando RF. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992; 73: 1261-67.
6. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92: 11553-57.
7. Campo MS, Grindlay GJ, O'Neil BW, Chandrachud LM, McGarvie GM, Jarrett WFH. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 1993; 74: 945-53.
8. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-63.
9. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993; 67: 315-22.
10. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Nad Acad Sci USA 1992; 89: 12180-84.
11. McNeil C. HPV vaccine treatment trials proliferate, diversify. J Natl Cancer Inst 1997; 89: 280-81.
12. Kreider JW, Howett MK, Wolfe SA. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature 1985; 317: 639-41.
13. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990; 64: 3151-56.
14. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995; 87: 796-802.
15. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 1997; 22: 219-25.
16. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class 1 pathway. Virology 1998; 240: 147-57.
17. Greenstone HL, Nieland JD, DeVisser KE, et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998; 95: 1800-05.
18. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13: 545-86.
19. Chen L, Mizuno MT, Singhal MC, et al. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 1992; 148: 2617-621.
20. Chen L, Thomas EK, Hu S, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88: 110-14.
21. Feltkamp MC, Smits HL, Vierboom MP, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993; 23: 2242-49.
22. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-27.
23. Connor ME, Stern PL. Loss of MHC class-I expression in cervical carcinomas. Int J Cancer 1990; 46: 1029-34.
24. Cromme FV, Airey J, Heemels M-T, et al. T -oss of transporter protein encoded by the TAP-1 gene is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179: 335-40.
25. Nardelli-Haefliger D, Roden RB, Benyacoub J, et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 1997; 65: 3328-36.
26. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol 1997; 71: 8467-74.
27. Ossevoort MA, Feltkemp MC, VanVeen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother 1995; 18: 86-94.
28. Ustav M, Stenlund A. Transient replication of BPV-1 requires two viral polypeptides encoded by the. E1 and E2 open reading frames. EMBO J 1991; 10: 449-57.
29. Selvakumar R, Borenstein LA, Lin YL, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol 1995; 69: 602-05.